Tarextumab

Tarextumab (OMP-59R5) is a cross-reactive, fully human IgG2 antibody that selectively inhibits Notch2 and Notch3 signaling. Tarextumab demonstrates broad-spectrum antitumor efficacy in xenograft models of epithelial tumors. Tarextumab can be used for the study of pancreatic cancer[1][2].

Product Specifications

CAS Number

[1359940-55-8]

Product Name Alternative

OMP 59R5; Anti-Human NOTCH2 Recombinant Antibody

UNSPSC

12352203

Target

Notch

Type

Inhibitory Antibodies

Related Pathways

Neuronal Signaling; Stem Cell/Wnt

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/tarextumab.html

Purity

99.83

Solubility

10 mM in DMSO

Smiles

[Tarextumab]

Molecular Weight

(142.94 kDa)

References & Citations

[1]Yen WC, et al. Targeting Notch signaling with a Notch2/Notch3 antagonist (tarextumab) inhibits tumor growth and decreases tumor-initiating cell frequency. Clin Cancer Res. 2015 May 1;21 (9) :2084-95. |[2]Fu W, et al. EGFR/Notch Antagonists Enhance the Response to Inhibitors of the PI3K-Akt Pathway by Decreasing Tumor-Initiating Cell Frequency. Clin Cancer Res. 2019 May 1;25 (9) :2835-2847.